NLRP3 and diabetic cardiomyopathy: Gypenosides can improve diabetic cardiomyopathy and CHD by inhibiting reactive oxygen species-mediated NLRP3 inflammasome activation (Lee et al., 2013; Zhang et al., 2018b).